TrialsgrambetaRCTs are beautiful

KATHERINE

2019

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

In 1,486 patients with HER2+ early breast cancer and residual invasive disease after neoadjuvant taxane + trastuzumab, adjuvant trastuzumab emtansine (T-DM1) reduced invasive disease-free survival events compared with trastuzumab.

Result

Efficacy: Invasive disease-free survivalHR 0.5

Below 1 favours trastuzumab emtansine (T-DM1), above 1 favours trastuzumab.

Event rates
Absolute difference
11.3 points

The absolute difference is derived from the event rates.

Also reported: 8.4-yr OS HR 0.66.

Original publication
Subtopic
HER2+ residual disease
Design
Open-label RCT
Relevance
Important: one of several pillars.
Source
von Minckwitz G, et al. N Engl J Med. 2019;380(7):617-628; Geyer CE, et al. N Engl J Med. 2025;392(3):249-257.doi 10.1056/NEJMoa1814017

Discussion & critique

Defined post-neoadjuvant escalation in HER2+ early breast cancer with residual disease as standard of care.